These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 18768188)
1. New targets for treatment of multiple sclerosis. Steinman L J Neurol Sci; 2008 Nov; 274(1-2):1-4. PubMed ID: 18768188 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Sinclair C; Mirakhur M; Kirk J; Farrell M; McQuaid S Neuropathol Appl Neurobiol; 2005 Jun; 31(3):292-303. PubMed ID: 15885066 [TBL] [Abstract][Full Text] [Related]
3. Comment on "Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis". van Noort JM; Amor S; Bajramovic JJ J Immunol; 2011 Jul; 187(1):3; author reply 3-4. PubMed ID: 21690329 [No Abstract] [Full Text] [Related]
4. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Rithidech KN; Honikel L; Milazzo M; Madigan D; Troxell R; Krupp LB Mult Scler; 2009 Apr; 15(4):455-64. PubMed ID: 19324981 [TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. Folio C; Mora MI; Zalacain M; Corrales FJ; Segura V; Sierrasesúmaga L; Toledo G; San-Julián M; Patiño-García A J Proteome Res; 2009 Aug; 8(8):3882-8. PubMed ID: 19492781 [TBL] [Abstract][Full Text] [Related]
6. A molecular trio in relapse and remission in multiple sclerosis. Steinman L Nat Rev Immunol; 2009 Jun; 9(6):440-7. PubMed ID: 19444308 [TBL] [Abstract][Full Text] [Related]
7. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Satoh JI; Tabunoki H; Yamamura T Mult Scler; 2009 May; 15(5):531-41. PubMed ID: 19389748 [TBL] [Abstract][Full Text] [Related]
8. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN. Steinman L Eur J Immunol; 2009 Sep; 39(9):2358-60. PubMed ID: 19681057 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of alphaB-crystallin and evidence of its role as a mediator of matrix gene expression in osteoarthritis. Lambrecht S; Verbruggen G; Elewaut D; Deforce D Arthritis Rheum; 2009 Jan; 60(1):179-88. PubMed ID: 19116904 [TBL] [Abstract][Full Text] [Related]
11. The differential amino acid requirement within osteopontin in alpha4 and alpha9 integrin-mediated cell binding and migration. Ito K; Kon S; Nakayama Y; Kurotaki D; Saito Y; Kanayama M; Kimura C; Diao H; Morimoto J; Matsui Y; Uede T Matrix Biol; 2009 Jan; 28(1):11-9. PubMed ID: 19000758 [TBL] [Abstract][Full Text] [Related]
12. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? Altintaş A; Saruhan-Direskeneli G; Benbir G; Demir M; Purisa S J Neurol Sci; 2009 Jan; 276(1-2):41-4. PubMed ID: 18845306 [TBL] [Abstract][Full Text] [Related]